DISEASE: Parathyroid carcinoma

Entry

H01558                      Disease

Name

Parathyroid carcinoma

Description

Parathyroid carcinoma (PC) is a highly aggressive endocrine tumor, with an annual incidence of less than 1 per million. Over 90% of patients present with excess parathyroid hormone (PTH), representing <1-5% of all patients with primary hyperparathyroidism. PC is associated with mutations in the HRPT2/CDC73 gene and with decreased parafibromin and calcium-sensing receptor (CASR) expression. Negative parafibromin staining together with a CDC73 gene mutation increases the likelihood of malignancy and also predicts the clinical outcome, namely local invasion and/or metastases and mortality. An increased mortality is predicted by either of these abnormality combined with down regulation of the calcium-sensing receptor (CaSR) expression.

Category

Cancer

Brite

Human diseases [BR:br08402]
Cancers
  Cancers of endocrine organs
   H01558  Parathyroid carcinoma
Human diseases in ICD-11 classification [BR:br08403]
02 Neoplasms
  In situ neoplasms, except of lymphoid, haematopoietic, central nervous system or related tissues
   2E6B  Carcinoma in situ of thyroid and other endocrine glands
    H01558  Parathyroid carcinoma

Related
pathway

hsa04928

Parathyroid hormone synthesis, secretion and action

Gene

CDC73/HRPT2 (mutation) [HSA:79577] [KO:K15175]
CASR [HSA:846] [KO:K04612]

Drug

Cinacalcet hydrochloride [DR:D03505]

Other DBs

ICD-11:

2E6B

ICD-10:

D09.3

MeSH:

D010282

Reference

PMID:26177319

Authors

Duan K, Mete O

Title

Parathyroid Carcinoma: Diagnosis and Clinical Implications.

Journal

Turk Patoloji Derg 31 Suppl 1:80-97 (2015)
DOI:10.5146/tjpath.2015.01316

Reference

PMID:26312219

Authors

McClenaghan F, Qureshi YA

Title

Parathyroid cancer.

Journal

Gland Surg 4:329-38 (2015)
DOI:10.3978/j.issn.2227-684X.2015.05.09

Reference

PMID:24035866

Authors

Costa-Guda J, Arnold A

Title

Genetic and epigenetic changes in sporadic endocrine tumors: parathyroid tumors.

Journal

Mol Cell Endocrinol 386:46-54 (2014)
DOI:10.1016/j.mce.2013.09.005

Reference

PMID:20510594

Authors

Givi B, Shah JP

Title

Parathyroid carcinoma.

Journal

Clin Oncol (R Coll Radiol) 22:498-507 (2010)
DOI:10.1016/j.clon.2010.04.007

Reference

PMID:25002250

Authors

Truran PP, Johnson SJ, Bliss RD, Lennard TW, Aspinall SR

Title

Parafibromin, galectin-3, PGP9.5, Ki67, and cyclin D1: using an immunohistochemical panel to aid in the diagnosis of parathyroid cancer.

Journal

World J Surg 38:2845-54 (2014)
DOI:10.1007/s00268-014-2700-2

Reference

PMID:26675091

Authors

Karaarslan S, Yurum FN, Kumbaraci BS, Pala EE, Sivrikoz ON, Akyildiz M, Bugdayci MH

Title

The Role of Parafibromin, Galectin-3, HBME-1, and Ki-67 in the Differential Diagnosis of Parathyroid Tumors.

Journal

Oman Med J 30:421-7 (2015)
DOI:10.5001/omj.2015.84

Reference

PMID:27001435

Authors

Cetani F, Pardi E, Marcocci C

Title

Update on parathyroid carcinoma.

Journal

J Endocrinol Invest 39:595-606 (2016)
DOI:10.1007/s40618-016-0447-3

Reference

PMID:21240254

Authors

Witteveen JE, Hamdy NA, Dekkers OM, Kievit J, van Wezel T, Teh BT, Romijn JA, Morreau H

Title

Downregulation of CASR expression and global loss of parafibromin staining are strong negative determinants of prognosis in parathyroid carcinoma.

Journal

Mod Pathol 24:688-97 (2011)
DOI:10.1038/modpathol.2010.236

» Japanese version

All links

Drug (1)   
   KEGG DRUG (1)   
Gene (4)   
   KEGG ORTHOLOGY (2)   
   KEGG GENES (2)   
Literature (8)   
   PubMed (8)   
All databases (13)   

Download RDF